Ashish  Khanna net worth and biography

Ashish Khanna Biography and Net Worth

CFO of Aptinyx
Mr. Khanna is chief financial officer and chief business officer of Aptinyx, with responsibilities that include finance, corporate and business development, alliance management, legal, and communications. He was previously vice president of corporate development at Naurex and managed its financing and transaction efforts, culminating in the company’s acquisition by Allergan. Prior to Naurex, Mr. Khanna served as director of business development at Vanda Pharmaceuticals. He was formerly a member of the cardiology strategic marketing team at Cordis Corporation, a Johnson & Johnson company. Earlier, Mr. Khanna was a strategy consultant with the Palladium Group and with the Strategic Advisory Services practice of Ernst & Young (now Capgemini). He serves on the board of directors of the Illinois Biotechnology Innovation Organization. Mr. Khanna received a B.S. in finance and B.A.S. in systems engineering from the University of Pennsylvania, as well as an M.B.A. from the Wharton School.

How do I contact Ashish Khanna?

The corporate mailing address for Mr. Khanna and other Aptinyx executives is 909 DAVIS STREET SUITE 600, EVANSTON IL, 60201. Aptinyx can also be reached via phone at (847) 871-0377 and via email at [email protected]. Learn More on Ashish Khanna's contact information.

Has Ashish Khanna been buying or selling shares of Aptinyx?

Ashish Khanna has not been actively trading shares of Aptinyx over the course of the past ninety days. Most recently, on Thursday, December 2nd, Ashish Khanna bought 45,000 shares of Aptinyx stock. The stock was acquired at an average cost of $2.26 per share, with a total value of $101,700.00. Learn More on Ashish Khanna's trading history.

Who are Aptinyx's active insiders?

Aptinyx's insider roster includes Robert Hombach (Director), Ashish Khanna (CFO), Joan Miller (Director), and Norbert Riedel (CEO). Learn More on Aptinyx's active insiders.

Ashish Khanna Insider Trading History at Aptinyx

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/2/2021Buy45,000$2.26$101,700.00View SEC Filing Icon  
1/18/2019Buy10,000$5.45$54,500.00View SEC Filing Icon  
6/25/2018Buy7,800$16.00$124,800.00View SEC Filing Icon  
See Full Table

Ashish Khanna Buying and Selling Activity at Aptinyx

This chart shows Ashish Khanna's buying and selling at Aptinyx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Aptinyx Company Overview

Aptinyx logo
Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Its lead product candidate NYX-783, an N-methyl-D-aspartate receptors (NMDAr) modulator that is in Phase I clinical trial to treat opioid use disorder, or OUD; and in preclinical trial for the treatment of alcohol use disorder, or AUD. The company has a research collaboration agreement with Allergan plc. Aptinyx Inc. was incorporated in 2015 and is headquartered in Evanston, Illinois.
Read More

Today's Range

Now: $0.10
Low: $0.09
High: $0.10

50 Day Range

MA: $0.08
Low: $0.06
High: $0.10

2 Week Range

Now: $0.10
Low: $0.01
High: $0.72

Volume

231,100 shs

Average Volume

1,317,051 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.27